Shopping Cart
- Remove All
- Your shopping cart is currently empty
Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $289 | In Stock | |
5 mg | $753 | In Stock | |
10 mg | $1,180 | In Stock | |
25 mg | $1,780 | In Stock | |
50 mg | $2,380 | In Stock |
Description | Romlusevimab (BRII-198) is a recombinant antibody targeting the spike protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with antiviral activity, used for research on COVID-19 infection. |
In vitro | Romlusevimab showed a high binding affinity for RBD with an equilibrium dissociation constant (KD) of 0.56 nM. The mixture of Amubarvimab and Romlusevimab blocks the binding of human ACE2 receptor to RBD, IC50 = 16.36 nM. The neutralizing activity of Romlusevimab against Neut99 was 2.50 μg/mL. [1] |
In vivo | Amubarvimab and Romlusevimab at a 1:1 mixture of 10 mg/kg or 50 mg/kg intritoneally injected into hamsters showed potent activity against SARS-CoV-2. [1] |
Alias | BRII-198, BRII198 |
Cas No. | 2509447-08-7 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.